Page 2 - Sohini Das

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Proton therapy expansion to put India high on global cancer care map

Rising capacity, cost advantage, and new centres position India as a key destination for advanced cancer care, though access gaps and affordability remain challenges

India EV sales double, mid-market surges as entry segment shrinks

EV volumes rise 87 per cent in FY26, with ₹20-30 lakh segment gaining share while entry-level adoption weakens due to affordability and product gaps

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Medical device makers push 'fair pricing' model amid MRP concerns

Medical device makers have urged a shift to a fair pricing model amid concerns over inflated MRPs, even as stakeholders remain divided on pricing practices in healthcare

Results preview: Pharma growth steady in Q4, but US drag weighs on margins

India's pharma and healthcare firms may post steady Q4 revenue growth, but weak US generics and rising costs are likely to keep margins under pressure

Maruti Suzuki retires Ignis; supply woes hit S-Presso and WagonR

Maruti Suzuki phases out Ignis amid weak demand, even as strong bookings and production constraints lead to supply shortages in Wagon R and S-Presso models

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

SML Mahindra Q4FY26 PAT rises 2.4% to ₹54 crore, top line surges 16%

Despite modest profit growth, SML Mahindra reports strong revenue gains and outlines plans to expand market share and enter electric bus segment

Q4 results preview: Automakers may report strong volume-led growth

Auto companies are likely to post strong volume-led growth in Q4FY26, but rising input costs and commodity inflation are beginning to weigh on margins across segments

Shipping bottlenecks squeeze pharma flows as Hormuz crisis impact deepens

India's pharmaceutical industry remains dependent on China for bulk drugs, particularly fermentation-based antibiotics, vitamins and intermediates

Scooters set to overtake motorcycles as EV shift reshapes India's 2W market

Replacement demand recovery is expected to support near-term growth, while rising electrification and changing consumer preferences may drive scooters to overtake motorcycles in the long run

Electric 2-wheeler maker Ather to cut aluminium content to ease costs

Ather plans to reduce aluminium content in scooters to cut costs and improve margins, with up to 15 per cent savings expected on its upcoming EL platform

From treatment to trend, slimming drug boom sparks misuse concerns

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Orbicular Pharma gets US FDA nod for generic Ozempic with Apotex

Orbicular Pharma and Apotex secure tentative US FDA approval for generic Ozempic, marking entry into fast-growing semaglutide market pending patent clearance

VW group targets 5% India passenger vehicle market share by decade-end

Automaker aims to double India market share with new models, alternate fuel push and potential entry into sub-4 metre SUV segment by 2030

Mercedes-Benz drives past West Asia war turmoil with Q1 India growth

Strong demand for top-end luxury cars and EVs helps the carmaker post 5% sequential growth despite volatility, currency pressure and rising import costs

IPM growth at 10.5% marks 5-qtr high on steady pricing, volume recovery

Indian pharma market's growth was led more by price increases that an uptick in consumption

Tesla lags new foreign entrants in India EV race despite global playbook

VinFast and BYD outpace the US EV giant with sharper pricing, faster localisation signals and wider networks, even as Tesla sticks to an import-led strategy

India needs to rethink IPO norms for biotech startups: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw urges IPO reforms, saying India's listing norms hinder biotech firms that need long R&D cycles before generating revenue